Professor R J Berry opened the meeting, at which the majority of the papers read were from the British National Lymphoma Investigation (BNLI). This was set up by Dr A M Jelliffe and colleagues in 1970. The central secretariat is based in the Department of Oncology, The Middlesex Hospital Medical School. Over 7500 patients from 46 centres in the UK have been registered with the study.
The morning session began with a historical review on Hodgkin's disease given by Dr A MJellift'e who spoke on the 'Changing prospects of cure'. In the 1940sthe accepted view of Hodgkin's disease (HD) by the medical profession was that it was inevitably fatal. Typically, pathologists avoided diagnosing HD and clinicians limited treatment to palliation with small doses of irradiation, disregarding the remarkable radiosensitivity of the disease. The publications of Vera Peters in 1950and 1958claiming 5-year survival of over 50% after irradiation for localized HD were completely ignored. A review of all the material available at the Middlesex Hospital from 1930 to 1952 revealed that 38% of patients with localized upper half disease survived 10years or longer. By the 1960s, irradiation was being given using a mantle type field which did not include the spleen because its import. ance was not then recognized. The early work of Jelliffe and colleagues indicated that a dose of 3500-4000 rad in 4 weeks gave the best chance of local cure. Kaplan's later work on the dose-response relationship indicated that reduction of the dose to 3000rad was followed by failure in 15% of cases. Kaplan's work also indicated the practicality of total lymph node irradiation (TN!) and irradiation became generally accepted as the only method of curing HD. Chemotherapy was not generally accepted as curative until the long-term follow up by de Vita and colleagues of MOPP-treated cases. It has since become evident that about a half of patients with generalized disease are curable with combination chemotherapy. The introduction of alternating regimens by Bonnadonna and colleagues has apparently improved the prospects of cure. One of the early studies of the BNLI compared MOPP with TNI for Stage IlIA HD. Initially it appeared that better results were obtained by TN!, but long-term follow up has shown that if the spleen is involved TN! is frequently followed by relapse. The development of more sensitive methods of organ imaging and a better understanding of the many other factors which affect the prognosis have led to the abandonment of staging laparotomy as a routine procedure and the adoption of a predictive Prognostic Index. Future improvement in the treatment of HD can be expected by avoiding unnecessary over-treatment, by the use of repeated biopsies to confirm the presence of relapse and by the earlier recognition and more effective treatment of opportunist infections. Radiotherapy provides the safest and most effective method of curing patients with localized HD when the Prognostic Index is good. Combination chemotherapy for more active and advanced HD may be improved by the use of alternating regimens, and by the use of autologous bone marrow preservation and very high-dose chemotherapy or whole body irradiation.
The success of the BNLI has been dependent on the support ofits Pathology Panel. Dr M H Bennett read a paper 'Hodgkin's disease: is Rye still relevant?' which showed that a critical histological review of all evaluable patients with Hodgkin's disease accepted for treatment in the BNLI between 1970and 1980has confirmed the prognostic usefulness of the Rye classification provided that the criteria of the Lukes and Butler classification are rigidly adhered to. In addition Dr Bennett presented an easily applied and reproducible histological subdivision of nodular sclerotic Hodgkin's disease into good prognosis (grade 1) and poor prognosis (grade 2) groups. This is based on the cellular composition of the nodules, nodes showing easily recognized areas oflymphocyte depletion or numerous pleomorphic Hodgkin's cells correlating with a significantly worse prognosis.
Dr J L Haybittle, Consultant Statistician to the BNLI, then gave a paper on 'Prognostic factors in Stage I and II Hodgkin's disease', reporting that a previous analysis of prognostic factors in Stage IA and IIA Hodgkin's disease, upper half, had been extended to a larger group of 878 patients and to include two other factors, serum albumin and haemoglobin. It was found that, in addition to the five factors originally identified as significantly affecting survival (age, sex, mediastinal involvement, pathological grade and ESR), serum albumin was also found to be significant, a lower albumin level predicting a poorer survival. Nevertheless, the addition of albumin to the original prognostic index added little to its ability to select out a poor prognostic group of about 18% of all patients. Patients with B-symptoms and/or lower half disease had also been added to the group, making a total of 1143 patients, and the analysis repeated. The results showed that when age, sex, pathological grade, ESR and albumin were taken into account, the presence of B-symptoms added nothing significant to the prediction of survival. In this larger group, the original prognostic index was still able to distinguish a poor prognostic group (about 23% ofthe whole) with a 60% survival rate at 10years.
The final HD paper of the morning session was on the BNLI experience in 'Advanced Hodgkin's disesase', given by Dr B W Hancock, the trial coordinator of this study. From 1970to 1975 the BNLI compared standard MOPP chemotherapy with MOP (no prednisone) in advanced HD. This showed a significant advantage for complete remission rates and 5·year survival in favour of MOPP (62% v. 38% and 66% v. 30%). Since that time studies had been directed at improving MOPP chemotherapy. Between 1976 and 1979 MOPP was compared with. B-MOPP (addition of bleomycin), and the effects of maintenance chemotherapy with CCNU, vinblastine and bleomycin were evaluated. No advantage was seen for B·MOPP or for maintenance therapy. The next study compared MOPP with LOPP (chlorambucil substituted for mustine) and the latter was found to give identical responses with far less toxicity. Throughout the period 1976-1980, combined modality therapy with radiotherapy to sites of original bulk disease, following MOPP therapy in pathologically staged I, II and IIIB or total nodal irradiation followed by LOPP in Stage lIlA disease, was evaluated, These studies showed no initial advantage for combined modality therapy but recent analysis suggests a possible improved long-term disease-free survival in patients receiving chemotherapy plus radiotherapy. The most recent study, started in 1983, compares LOPP alone with LOPP alternating with the potentially non-cross-resistant regimen of EVAP (etoposide, vinblastine, adriamycin, prednisolone) . Over 250 patients have now been entered.
The afternoon session began with two papers on the biology and management of low-grade non-Hodgkin's lymphoma (NHL). Dr K A MacLennan, a member of the BNLI pathology panel, gave a histological review of follicular lymphomas which are Bcell neoplasms that architecturally and cytologically resemble the normal germinal centre. In the BNLI classification of NHL, follicular lymphomas are subdivided into three groups -predominantly small, mixed small and large and predominantly large cell types -by assessing the percentage oflarge lymphoid cells present within the neoplastic follicles. The commonest subtype of follicular lymphoma recognized in the BNLI studies is follicular lymphoma, small, and it has recently become apparent that in this supposedly histologically uniform group, the disease was unusually aggressive in a third of patients. It was therefore decided to undertake a critical morphological review of the diagnostic lymph node biopsies of all patients recorded in the files of the BNLI as having follicular lymphoma small, in an attempt to predict histologically those patients who would develop aggressive disease. Many parameters were studied, but analysis of survival data revealed only three to have prognostic significance: (1) an excess of large non-cleaved cells (>20% <30%); (2) increased mitotic activity within the neoplastic follicles (3jHPF); (3) the presence of an excess of small follicular blast cells. One or more of these parameters was identified in 17% of cases of follicular lymphoma, small, and these patients had a significantly decreased survival (P<O.Ol). However, it is apparent that these criteria are insufficient to identify all the patients with clinically aggressive disease and further histological study is required.
This was followed by a report from Dr G Vaughan Hudson on the 'BNLI management of low-grade NHL', who stated that since 1974,921Grade I lymphomas have been registered with the BNLI. In localized Journal of the Royal Society of Medicine Volume 80 February 1987 123 disease a randomized trial between local radiotherapy and local radiotherapy followed by 6 months chlorambucil was completed between 1974 and 1981. Of146 patients who were entered, over 90% went into remission. The 5-year survival was just over 70% in both groups. At present the BNLI treatment for localized NHL is local radiotherapy. In generalized disease 180 patients were randomized between chlorambucil (CHL) and COP (cyclophosphamide, vincristine and prednisone) between 1977and 1981. The CR rate was similarin both arms at approximately 60%. The S-year survival of the CHL group was 58% and the COP group 65%. Since June 1981, 300 patients have been entered into the present study, where patients have been randomized according to whether they have aggressive ('B' symptoms, rapid tempo, or critical organs involved) or non-aggressive disease. Comparison of the overall survival of the non-aggressive patients with the aggressive cases has confirmed that these are two significantly different subgroups <x 2 = 23.9). In the non-aggressive patients the 2-year survival following low-dose symptomatic radiotherapy is 92% and following chlorambucil is 86%, and in the aggressive patients is 74% in the chlorambucil group and 63% in the TBI group. At present the BNLI are analysing all the small-cell follicular Iymphomas and are trying to correlate the aggressive clinical behaviour with more aggressive histological subtypes.
Dr DC Linch, a BNLI trial coordinator, gave a comprehensive paper on the 'Approaches to treatment in high-grade NHL'. Local radiotherapy is the treatment of choice for Stage IjIE large cell lymphomas, with over 90% of thoroughly staged patients having long-term disease-free survival. The treatment of choice for other histological subcategories and for Stage II disease is less clear, but patients with gastrointestinal disease and bulk disease in other sites should probably receive chemotherapy as primary treatment. Single-agent chemotherapy was introduced for the treatment of high-grade lymphomas in the early 1960s. In 1976 McKelvey and colleagues reported the improved results of a combination chemotherapy regimen containing an anthracycline (CHOP). The BNLI has treated 361 unselected Stage III/IV patients with a modification ofthis regimen over the decade 1974-1984: nearly half the patients were aged over 60 years. Eighty percent of patients responded to this regimen, with 47% of all patients achieving a complete remission. Of patients achieving CR, the actuarial disease-free survival at 5 years was 62%. The actuarial survival of the whole series of patients at 5 years was 35.5% and these results clearly leave room for improvement. Various approaches to improving CHOP therapy have been attempted. The Seattle group have investigated combined modality therapy with CHOP and radio. therapy. A third approach has been to use sequential or alternating regimens of hopefully non-cross. resistant drug combinations (CHOP-HOAP-IMVP16, ProMACE·MOPP) and high CR rates and 2-year survivals have been reported.
The results from these newer regimens are encouraging, but great difficulty exists in precise evaluation of some of the data. Many centres are secondary or tertiary referral centres and selection may occur. In this context it should be noted that the presence of B symptoms at diagnosis is the major factor predicting poor response and very ill patients may have been treated (off-protocol and excluded) prior to transfer. Other series also include Stage II patients and the long-term survival of Stage II patients in the BNLI CHOP studies is nearly twice that of Stage III/IV patients. Confusion also exists over histology and many series include diffuse small cleaved-cell lymphomas, a category that would be considered as low-grade by the BNLI. Furthermore, some centres exclude patients who do not receive certain quantities of drugs, thus eliminating early deaths. It must therefore be concluded that there is as yet no firm proof that any of these regimens are superior to CHOP. There is clearly a desperate need for a large randomized controlled trial in this field. At present the BNLI is investigating the use of IMVP16 or very high-dose chemotherapy with autologous bone marrow rescue in those patients not in CR after 3 courses of CHOP as a prelude to such a randomized trial.
The final paper of the session, given by Professor T J McElwain from the Institute of Cancer Research and Royal Marsden Hospital, was on 'Hodgkin's disease in childhood'. This has a good prognosis, with 90% of patients being disease-free and probably cured after modern treatment. With effective combination therapy it is no longer necessary to document occult disease in the abdomen by staging laparotomy and splenectomy, which in childhood carries a major risk of subsequent morbidity due to pneumococcal and H. influenzae septicaemia. Nor is it necessary to use extended field radiotherapy for patients with early stage disease. This is associated with inhibition of bone growth and should be avoided where possible. Favourable Stage I disease (high cervical nodes, not bulky and not lymphocyte-depleted histology) can be treated with involved field radiation, and the few who relapse can be expected to be cured by combination chemotherapy. This approach to treatment is a sub-ject of a study currently organized by the United Kingdom Cancer Study Group. Unfavourable Stage I, most Stage II and all Stage III disease should be treated with chemotherapy. There is evidence that irradiation of bulky disease above the diaphragm following chemotherapy is associated with a low relapse rate. Stage IIA disease with small-volume cervical nodes or inguinal nodes only can be treated with involved field irradiation and any relapses retrieved with chemotherapy. Stage IV disease needs chemotherapy and here new agents and combinations of chemotherapy need to be explored in children who relapse or who have poor prognosis disease. The aim of such chemotherapy programmes is to reduce the carcinogenic risk associated with alkylating agents and procarbazine and also to develop programmes which do not sterilize males. Since, with most commonly used chemotherapy combinations, the most important late side effect is likely to be the induction of acute myeloblastic leukaemia and possibly other tumours, it is essential to assess this risk in children during the next few years, as has been done in adults.
Professor R J Berry closed the meeting by saying that the treatment of lymphoma has been one of the great success stories of modem cancer managementa success brought about by a fusion of traditional skills and new diagnostic and therapeutic techniques. While much has been achieved, much more remains to be done. The gains will be smaller but nonetheless worthwhile -minimizing upsetting treatment for those not needing it and maximizing effective treatment for those who do. It is still a challenging prospect. To Professor Tom Stapleton, President of the Section of Paediatrics, must go all the credit and more for the inspiration and organization of this meeting, probably the most ambitious event ever organized by the Section of Paediatrics. In particular, getting a large number of Chinese speakers to attend was a remarkable diplomatic and organizational achievement. The opening session was honoured by the presence of HRH The Princess Anne, and the twoday meeting comprised 16 papers from the People's Republic of China, 4 from Africa, 6 from the UK, and a series of posters, films, and a video.
Gillian Vaughan Hudson
The meeting opened with papers on general topics. The first presentation was by Dr A W Chung, who was intimately involved with the development of the health care system in China from the time of liberation in 1949until his appointment as Assistant Director-General at the World Health Organization. He described how child health care has developed in China, and demonstrated how attention to infant feeding, immunization and the control of bacterial and parasitic disease have brought about a great reduction in infant morbidity and mortality. Dr Honggul Li (Chief, Division for Policy and Planning, State Family Planning Commission) and Dr J Guo gave a paper on population control policy in China, describing the aims of the policy for late marriage, late birth and one child per marriage. Dr A G Wasunna (Nairobi) gave a paper on family planning in Kenya, and Dr A S Da Gama (Mozambique) described the problems facing those trying to promote child health in Mozambique. Dr Y Wang (Sichuan) presented a study of the Lieu people, one of a number of ethnic minorities in China. Professor L Wang (Wuhan, China) outlined the clinical work, teaching and research of a university paediatric department in China.
A number of special topics were covered. Dr X Meng (Heilongjang, China) described the clinical and pathological features of Keshan disease, a form of cardiomyopathy endemic in certain parts of China.
